Cargando…

Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma

BACKGROUND & AIMS: Little is known about molecular biomarkers that predict the response and prognosis in unresectable hepatocellular carcinoma (HCC) treated with programmed death (PD)-1 inhibitors. METHODS: A total of 62 HCC patients who underwent next-generation sequencing were retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Kai, Zhang, Ding, Chen, Yanan, Lu, Wenfeng, Huang, Mengli, Cai, Jinping, Chen, Shiqing, Bei, Ting, Bai, Yuezong, Lv, Jian, Fu, Yong, Zhang, Haibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086239/ https://www.ncbi.nlm.nih.gov/pubmed/37056769 http://dx.doi.org/10.3389/fimmu.2023.1116057

Ejemplares similares

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer.
por: Foulkes, W. D., et al.
Publicado: (1993)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
por: Yue, Zhi-Xia, et al.
Publicado: (2019)

Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients
por: Wei, Jia, et al.
Publicado: (2021)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
por: Jia, Meng, et al.
Publicado: (2022)

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
por: Aoki, Tomoko, et al.
Publicado: (2020)

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
por: Hanamura, Ichiro
Publicado: (2021)

Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma
por: Rao, Pulivarthi H, et al.
Publicado: (2004)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report
por: Chen, Kai-Bo, et al.
Publicado: (2022)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

Chromosome 20q Amplification Regulates in Vitro Response to Kinesin-5 Inhibitor
por: Jackson, Aimee L., et al.
Publicado: (2008)

Chromosome 8q as the most frequent target for amplification in early gastric carcinoma
por: KANG, JI UN
Publicado: (2014)

Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study
por: Xiang, Xiaosong, et al.
Publicado: (2023)

Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma
por: Qi, Feng, et al.
Publicado: (2021)

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
por: Lundgren, Katja, et al.
Publicado: (2008)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

The chromosome 11q13.3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment
por: Zhang, Weimin, et al.
Publicado: (2018)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Gain of Chromosome 20q Is an Indicator of Poor Prognosis in Colorectal Cancer
por: Postma, C., et al.
Publicado: (2007)

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
por: Han, Si-Chong, et al.
Publicado: (2023)

Analysis of chromosome 22q11 copy number variations by multiplex ligation-dependent probe amplification for prenatal diagnosis of congenital heart defect
por: Zhang, Jingjing, et al.
Publicado: (2015)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Amplification of the 20q Chromosomal Arm Occurs Early in Tumorigenic Transformation and May Initiate Cancer
por: Tabach, Yuval, et al.
Publicado: (2011)

Infertility in a man with oligoasthenozoospermia associated with mosaic chromosome 22q11 deletion
por: Liu, Yanyan, et al.
Publicado: (2018)

Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report
por: He, Yanxin, et al.
Publicado: (2021)

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
por: Defferrari, R, et al.
Publicado: (2015)

Early‐like differentiation status of systemic PD‐1(+) CD8 (+) T cells predicts PD‐1 blockade outcome in non‐small cell lung cancer
por: Khanniche, Asma, et al.
Publicado: (2022)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

Chromosome 11q13 deletion syndrome
por: Kim, Yu-Seon, et al.
Publicado: (2016)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study
por: Cheng, Daoan, et al.
Publicado: (2023)

Genomic amplification of chromosome 20q13.33 is the early biomarker for the development of sporadic colorectal carcinoma
por: Bui, Vo-Minh-Hoang, et al.
Publicado: (2020)

Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma
por: Yu, Ming-Chin, et al.
Publicado: (2021)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gbmf9uenv9dj841q5kl727dih1